Evolus Inc reports results for the quarter ended December 31 - Earnings Summary

• Evolus Inc EOLS.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of six analysts for the quarter was for earnings of 4 cents per share. Wall Street expected results to range from 2 cents to 8 cents per share.

• Revenue rose 29.4% to $78.95 million from a year ago; analysts expected $78.26 million.

• Evolus Inc's reported EPS for the quarter was a loss of 11 cents​.

• The company reported a quarterly loss of $6.79 million.

• Evolus Inc shares had risen by 29.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 117.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Evolus Inc is $25.00

This summary was machine generated from LSEG data March 5 at 02:25 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)